Although GH therapy has a good safety profile in girls with TS, close monitoring of IGF1 levels, abnormal glucose tolerance, reduced insulin sensitivity, benign intracranial hypertension, scoliosis and other skeletal changes at intervals of 3–6 months-is recommended [6, 7]. Here, IGF1 is linked to pseudotumor cerebri.